Skip to main content

Celera Diagnostics Strikes Deals With Quest, LabCorp

NEW YORK, Oct. 2 - Celera Diagnostics today said it has signed a pair of collaborations with Quest Diagnostics and Laboratory Corporation of America to determine the "clinical utility" of lab tests for a variety of diseases.


Terms of the deal call for Quest to receive exclusive yet temporary access to markers with potential clinical usefulness in cardiovascular disease and diabetes. LabCorp gets that deal but only for Alzheimer's disease and breast and prostate cancer.


In exchange, Celera Diagnostics, which will run the disease association studies for the collaboration in-house, said it will become "a preferred vendor" to both clinical diagnostics powerhouses.


Click here for more information on the LabCorp deal, and here for the Quest deal.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.